INVA Company Profile and Key Details

Q: Who are the executives of INVA?

Mr. Pavel Raifeld C.F.A.Chief Executive OfficerMs. Marianne Zhen CPAChief Accounting Officer & Sec.

NASDAQ : INVA

Innoviva

$20.74

0.08+0.39%

At Close 4:00 PM

63.81

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Innoviva, Inc. (INVA) stock surged +0.39%, trading at $20.74 on NASDAQ, up from the previous close of $20.66. The stock opened at $20.57, fluctuating between $20.35 and $20.78 in the recent session.

Stock Snapshot

20.66

Prev. Close

1.53B

Market Cap

20.35

Day Low

4.51

P/E Ratio

4.6

EPS (TTM)

2.21

Cash Flow per Share

20.57

Open

73.81M

Number of Shares

20.78

Day High

91.48%

Free Float in %

10.59

Book Value

623.37K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 25, 2026	20.70	20.78	20.35	20.74	623.37K
Sep 24, 2026	20.28	20.79	20.28	20.66	1.07M
Sep 23, 2026	21.11	21.36	20.23	20.24	3.67M
Sep 21, 2026	21.10	21.27	21.00	21.04	688.52K
Sep 18, 2026	20.93	21.18	20.85	21.14	1.42M
Sep 17, 2026	21.22	21.42	21.00	21.05	900.19K
Sep 16, 2026	20.86	21.24	20.86	21.20	715.4K
Sep 15, 2026	20.86	20.88	20.50	20.84	601.19K
Sep 14, 2026	20.93	21.11	20.69	20.90	660.71K
Sep 11, 2026	20.84	20.88	20.45	20.66	727.35K
Sep 10, 2026	21.16	21.24	20.58	20.62	836.38K
Sep 09, 2026	21.16	21.41	20.77	21.13	835.96K
Sep 08, 2026	21.06	21.51	20.87	21.34	782.19K
Sep 04, 2026	21.20	21.36	21.09	21.33	563.38K
Sep 03, 2026	21.48	21.48	21.04	21.35	612.26K
Sep 02, 2026	21.27	21.48	21.22	21.35	600.6K
Sep 01, 2026	20.97	21.18	20.94	21.08	798.74K
Aug 31, 2026	20.97	21.05	20.68	20.77	877.3K
Aug 28, 2026	20.96	21.07	20.80	20.97	527.01K
Aug 27, 2026	20.99	21.10	20.86	20.96	488.06K

Contact Details

Burlingame, CA 94010

United States

https://www.inva.com 650 238 9600

About Company

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Stock Peers

ARGX

-2.73-0.28%

argenx SE$959.49 REGN

-7.98-1.00%

Regeneron Pharmaceuticals, Inc.$788.04 VRTX

3.81+0.73%

Vertex Pharmaceuticals Incorporated$526.19 MDGL

3.35+0.65%

Madrigal Pharmaceuticals, Inc.$516.56 UTHR

3.24+0.69%

United Therapeutics Corporation$475.45 ONC

0.88+0.24%

BeOne Medicines AG$360.85 KRYS

0.86+0.25%

Krystal Biotech, Inc.$345.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

2.48+0.83%

Ligand Pharmaceuticals Incorporated$301.52 PRAX

-1.01-0.36%

Praxis Precision Medicines, Inc.$280.78

Company Overview

Innoviva, Inc. (NASDAQ:INVA) closed at $20.74 USD, gaining $0.08 (0.39%) from the previous close of $20.66. The stock is currently mid-range between its 52-week high and low $16.52 and $25.15. With a market capitalization of about $1.53 billion, Innoviva, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 810.51 thousand shares, in line with its 52-week average. Headquartered in Burlingame, CA, Innoviva, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pavel Raifeld, the company employs approximately 159 people and listed since October 05, 2004. Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 5.37%, SMA50 13.31%, SMA200 18.27%). The stock’s 14-day RSI is 67.64 (firm momentum), while the ATR of 0.76 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.91% below its high and over 42.49% above its low. Average 10-day trading volume of 1.40 million shares is significantly above the 3-month average of 777.49 thousand, indicating heightened recent market interest.

Valuation Metrics

Innoviva, Inc. trades at a P/E ratio of 4.26, slightly below the S&P 500 average, with a price-to-sales ratio of 3.45 and a price-to-book ratio of 1.23 suggesting the stock is closer to book value. The P/FCF stands at 8.13, also above market averages.

Dividend & Fair Value

Innoviva, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $60.80. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Innoviva, Inc. generated EPS of $1.39 over the past year. Five-year average earnings growth is -24.0%. Wall Street analysts project EPS growth of -15.37% annually over the next five years. The latest quarter delivered EPS of $1.14. The next quarter is forecast at $0.38. Next year's EPS is expected at -$50.90. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $46.00 to $17.00. The high target offers 121.79% upside. The low target suggests -18.03% downside. The mean target is $37.33. This offers 79.99% upside. Innoviva, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 05, 2026, missed forecasts by 161.47%. The prior quarter beat by 486.05%. Over the last six quarters, Apple has recorded several small beats. These include -13.79% in May 07, 2025.

Shareholding & Insider Activity

Innoviva, Inc. has 72.25 million shares outstanding. The public float is 67.65 million shares, elevated short interest at 12.95% of float. This equals 6.89 million shares. The short ratio is 9.19 days. Institutional investors hold 109.14% of the float. Insiders own 0.99%. DENNER ALEXANDER J holds 5.66 million shares, Aguiar Michael W has 980.91 thousand shares and Winningham Rick E has 690.11 thousand shares.

Frequently Asked Questions

What is the current Innoviva, Inc. (INVA) stock price?

Innoviva, Inc. (NASDAQ: INVA) stock price is $20.74 in the last trading session. During the trading session, INVA stock reached the peak price of $20.78 while $20.35 was the lowest point it dropped to. The percentage change in INVA stock occurred in the recent session was 0.39% while the dollar amount for the price change in INVA stock was $0.08.

INVA's industry and sector of operation?

The NASDAQ listed INVA is part of Biotechnology industry that operates in the broader Healthcare sector. Innoviva, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of INVA?

Mr. Pavel Raifeld C.F.A.
Chief Executive Officer
Ms. Marianne Zhen CPA
Chief Accounting Officer & Sec.

How INVA did perform over past 52-week?

INVA's closing price is 25.55% higher than its 52-week low of $16.52 where as its distance from 52-week high of $25.15 is -17.54%.

How many employees does INVA have?

Number of INVA employees currently stands at 159.

Link for INVA official website?

Official Website of INVA is: https://www.inva.com

How do I contact INVA?

INVA could be contacted at phone 650 238 9600 and can also be accessed through its website. INVA operates from 1350 Old Bayshore Highway, Burlingame, CA 94010, United States.

How many shares of INVA are traded daily?

INVA stock volume for the day was 623.37K shares. The average number of INVA shares traded daily for last 3 months was 810.51K.

What is the market cap of INVA currently?

The market value of INVA currently stands at $1.53B with its latest stock price at $20.74 and 73.81M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Innoviva, Inc. (INVA) stock surged +0.39%, trading at $20.74 on NASDAQ, up from the previous close of $20.66. The stock opened at $20.57, fluctuating between $20.35 and $20.78 in the recent session.

Stock Snapshot

20.66

Prev. Close

1.53B

Market Cap

20.35

Day Low

4.51

P/E Ratio

4.6

EPS (TTM)

2.21

Cash Flow per Share

20.57

Open

73.81M

Number of Shares

20.78

Day High

91.48%

Free Float in %

10.59

Book Value

623.37K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 25, 2026	20.70	20.78	20.35	20.74	623.37K
Sep 24, 2026	20.28	20.79	20.28	20.66	1.07M
Sep 23, 2026	21.11	21.36	20.23	20.24	3.67M
Sep 21, 2026	21.10	21.27	21.00	21.04	688.52K
Sep 18, 2026	20.93	21.18	20.85	21.14	1.42M
Sep 17, 2026	21.22	21.42	21.00	21.05	900.19K
Sep 16, 2026	20.86	21.24	20.86	21.20	715.4K
Sep 15, 2026	20.86	20.88	20.50	20.84	601.19K
Sep 14, 2026	20.93	21.11	20.69	20.90	660.71K
Sep 11, 2026	20.84	20.88	20.45	20.66	727.35K
Sep 10, 2026	21.16	21.24	20.58	20.62	836.38K
Sep 09, 2026	21.16	21.41	20.77	21.13	835.96K
Sep 08, 2026	21.06	21.51	20.87	21.34	782.19K
Sep 04, 2026	21.20	21.36	21.09	21.33	563.38K
Sep 03, 2026	21.48	21.48	21.04	21.35	612.26K
Sep 02, 2026	21.27	21.48	21.22	21.35	600.6K
Sep 01, 2026	20.97	21.18	20.94	21.08	798.74K
Aug 31, 2026	20.97	21.05	20.68	20.77	877.3K
Aug 28, 2026	20.96	21.07	20.80	20.97	527.01K
Aug 27, 2026	20.99	21.10	20.86	20.96	488.06K

Contact Details

Burlingame, CA 94010

United States

https://www.inva.com 650 238 9600

About Company

Stock Peers

ARGX

-2.73-0.28%

argenx SE$959.49 REGN

-7.98-1.00%

Regeneron Pharmaceuticals, Inc.$788.04 VRTX

3.81+0.73%

Vertex Pharmaceuticals Incorporated$526.19 MDGL

3.35+0.65%

Madrigal Pharmaceuticals, Inc.$516.56 UTHR

3.24+0.69%

United Therapeutics Corporation$475.45 ONC

0.88+0.24%

BeOne Medicines AG$360.85 KRYS

0.86+0.25%

Krystal Biotech, Inc.$345.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

2.48+0.83%

Ligand Pharmaceuticals Incorporated$301.52 PRAX

-1.01-0.36%

Praxis Precision Medicines, Inc.$280.78

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Over the trailing twelve months, Innoviva generated $324.26M in revenue, or $8.99 per share. Gross margin was 75.84%, operating margin 35.12%, and net profit margin 55.42%. Returns are exceptional, with ROA at 14.45% and ROE at 26.63%.
On valuation metrics, Innoviva trades at a P/E of 4.26, P/S of 3.45 and P/B of 1.23. The current ratio is 16.01 and quick ratio is 15.18. Operationally, the company’s inventory turnover is 3.06 and cash conversion cycle is 197.95 days. Debt-to-equity is 0.22, supported by a cash flow-to-debt ratio of 0.71.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Innoviva posted revenue of $324.26M, down slightly from $331.34M in the prior quarter. Gross profit was $245.92M (margin 75.84%). Operating income was $113.89M (margin 35.1%). Net income was$179.72M (EPS - $1.91).
The company ended the quarter with $193.51M in cash and short-term investments, a total debt of $449.08M, and net debt of $255.56M. Total assets were $1.24B, with equity of $674.96M. Financials further reflected stability, with operating cash flow of $141.06M, free cash flow of $140.65M, and capital expenditures of - $411.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Innoviva, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.45%, with price expected at $20.44 by October 09, 2026, within a range of $20.15 to $20.70 3-Month Outlook: Projected rise of 22.61%, reaching $25.43 by December 24, 2026, with a range of $24.90 to $26.00. 1-Year Outlook: Projected gain of 11.33%, with price at $23.09 by September 24, 2027, within a range of $22.66 to $23.61.

Key Takeaways

Innoviva, Inc. (NASDAQ:INVA) shares are flat -2.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Innoviva, Inc. trading at a premium to the broader market with a P/E of 4.26. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $31.00, suggesting 49.47% upside. Our AI forecast model points to short-term weakness (-1.45% over two weeks), a medium-term rise (22.61% over three months), and a longer-term gain (11.33% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Innoviva, Inc. (INVA) stock price?

INVA's industry and sector of operation?

Who are the executives of INVA?

Mr. Pavel Raifeld C.F.A.
Chief Executive Officer
Ms. Marianne Zhen CPA
Chief Accounting Officer & Sec.

How INVA did perform over past 52-week?

INVA's closing price is 25.55% higher than its 52-week low of $16.52 where as its distance from 52-week high of $25.15 is -17.54%.

How many employees does INVA have?

Number of INVA employees currently stands at 159.

Link for INVA official website?

Official Website of INVA is: https://www.inva.com

How do I contact INVA?

INVA could be contacted at phone 650 238 9600 and can also be accessed through its website. INVA operates from 1350 Old Bayshore Highway, Burlingame, CA 94010, United States.

How many shares of INVA are traded daily?

INVA stock volume for the day was 623.37K shares. The average number of INVA shares traded daily for last 3 months was 810.51K.

What is the market cap of INVA currently?

The market value of INVA currently stands at $1.53B with its latest stock price at $20.74 and 73.81M of its shares outstanding.

Employees	159
Beta	0.33
Sales or Revenue	$324.26M
5Y Sales Change%	0.833%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	159
Beta	0.33
Sales or Revenue	$324.26M
5Y Sales Change%	0.833%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

INVA Company Profile and Key Details

Innoviva

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights